title: [Effects of different antihypertensive strategies on reversing urinary albumin excretion].
abstract: OBJECTIVE
  To explore the effects of different antihypertensive strategies on blood pressure and urinary albumin excretion in patients with hypertension and microalbuminuria.
  
  
  METHODS
  For this multi-center, randomized, positively controlled clinical trial, a total of 531 patients with mild-to-moderate essential hypertension and microalbuminuria were enrolled. They were divided randomly into calcium channel blocker (CCB), angiotensin II receptor antagonist (ARB) and CCB+ARB groups. The whole treatment period was 6 months.
  
  
  RESULTS
  According to ANOVA analysis, the post-therapeutic urinary albumin level decreased 20.6, 27.6 and 30.9 mg/L in CCB, ARB and CCB+ARB groups respectively (P = 0.067). And the extents of urinary albumin reduction were 31.1 and 6.6 mg/L in patients with controlled and uncontrolled blood pressure respectively (P < 0.001).
  
  
  CONCLUSIONS
  Effective antihypertensive therapy is a key for decreasing urinary albumin excretion in hypertensive patients. As compared with calcium antagonists, ARB-containing regimens appear to be better in reducing urinary albumin.
authors.affiliation: Heart Center, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Hong-yi
authors.initials: HY
authors.lastname: Wang
authors.affiliation: Heart Center, Peking University People's Hospital, Beijing 100044, China. Email: nlsun@263.net.
authors.forename: Ning-ling
authors.initials: NL
authors.lastname: Sun
authors.affiliation: Heart Center, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Yuan-yuan
authors.initials: YY
authors.lastname: Chen
authors.affiliation: Heart Center, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Zhi-yi
authors.initials: ZY
authors.lastname: Ma
authors.affiliation: Heart Center, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Xi
authors.affiliation: Heart Center, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Lu-yan
authors.initials: LY
authors.lastname: Wang
authors.affiliation: Heart Center, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Fan
authors.initials: F
authors.lastname: Yang
mesh_terms: D000368:Aged; D000419:Albuminuria / Q000188:drug therapy*; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D000075222:Essential Hypertension; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000652:urine; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers